MARKET

TLSI

TLSI

TriSalus Life Sciences Inc.
NASDAQ
4.220
-0.050
-1.17%
After Hours: 4.319 +0.099 +2.36% 19:34 07/24 EDT
OPEN
4.300
PREV CLOSE
4.270
HIGH
4.320
LOW
4.000
VOLUME
189.76K
TURNOVER
--
52 WEEK HIGH
7.95
52 WEEK LOW
2.200
MARKET CAP
259.18M
P/E (TTM)
-2.9925
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TLSI last week (0713-0717)?
Weekly Report · 5d ago
Press Release: TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
Dow Jones · 07/16 21:57
TriSalus Life Sciences schedules Q2 2026 results conference call
PUBT · 07/16 20:05
Weekly Report: what happened at TLSI last week (0706-0710)?
Weekly Report · 07/13 09:33
Weekly Report: what happened at TLSI last week (0629-0703)?
Weekly Report · 07/06 09:35
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
NASDAQ · 06/30 11:59
TriSalus Life Sciences names Richard Henry Marshall as chief medical officer in initial beneficial ownership filing
PUBT · 06/29 20:31
Weekly Report: what happened at TLSI last week (0622-0626)?
Weekly Report · 06/29 09:33
More
About TLSI
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. It is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method.

Webull offers TriSalus Life Sciences Inc stock information, including NASDAQ: TLSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSI stock methods without spending real money on the virtual paper trading platform.